2005 Detection of an active substance for killing of murine fibrosarcoma tumor cells by releasing apoptosis effectors, comprises adding a catalase inhibitor and detecting catalase activity and apoptotis cells Patent Assignee DE102005027796 (B4)
Detection of an active substance for killing of murine fibrosarcoma tumor cells by releasing apoptosis effectors, sample preparations are arranged in cell culture medium in a separate culture container. Detection of an active substance for killing of murine fibrosarcoma tumor cells by releasing apoptosis by effectors, sample preparations are arranged in cell culture medium in a separate culture container. The tumor cells or additionally cultured effector cells are cultured to a suitable cell density that leads to apoptosis of the tumor cells by the addition of a catalase inhibitor that acts on the exterior of the tumor cells followed by incubation of the sample preparations. The sample preparations with active substances containing a higher proportion of apoptotic tumor cells are detected.; The effector triggers apoptosis of the tumor cells by inhibiting the effect of the extracellular catalase of the tumor cells. An independent claim is included for an active substance. ACTIVITY: Cytostatic. MECHANISM OF ACTION: Catalase inhibitor.
2017 Taste modulating flavoring substances PCT/EP2017/065457 – WO2018233841 (A1)
The invention relates to mixtures comprising compounds of formula (I) and at least one substance which produces one or more unpleasant taste impressions, preferably one or more of the following taste impressions: bitter, astringent, or metallic. The invention further relates to orally applicable products containing a mixture according to the invention, and to a method for producing the mixtures and products according to the invention. The invention further also relates to the use of a compound of formula (I) for masking or reducing an unpleasant taste impression, and to certain novel compounds of formula.
2021 Dihydrochalcone Derivatives: Enhancing Flavor as Sweet Tasting and Sweet Modulating Agents WO2023065059A1
The present invention introduces a unique compound or mixture of compounds (formula I) designed to enhance and optimize the flavor of sweet substances. Its purpose is to elevate the sweet flavor, improve mouthfeel, reduce acidity, and eliminate bitter aftertaste or unwanted off-tastes in sweet substances. This patent also encompasses a composition comprising the formula I compound, one or more sweet substances, and optionally a sweet taste modulating substance. Additionally, it introduces a product utilizing this composition. Furthermore, the invention provides a method for effectively modulating and optimizing the flavor of various sweet substances. It offers a straightforward approach to improve the overall taste experience. Notably, the invention also encompasses a method for the production of the formula I compound or compound mixtures. This process ensures the availability of the key ingredient. Lastly, the invention highlights specific new compounds or compound mixtures and their application as flavorful substances, especially in the context of sweetness and taste modulation. This breakthrough discovery opens new possibilities for enhancing naturally the taste and enjoyment of various products.
Bicoll in the Press
Bicoll: The First Sino-German Biotechnology Company, Lamottke, C. Haug, N. Feling, Chapter: IV, The Experience of European Pharma Companies, in The Chemical and Pharmaceutical Industry in China – Opportunities and Threats for Foreign Companies, Festel, G.; Kreimeyer, A.; Oels, U.; Zedtwitz, M.v. (Hrsg.); Springer, 2005, ISBN: 3-540-22544-7
Declining Biodiversity – A Threat to Future Pharmaceutical Development, The Bulletin – Hong Kong Chamber of Commerce, Special Reports; Jan. 2006, pp. 48-52 Authors:Dr. Nicole Feling, Dr. Kai Lamottke
R&D takes off in Shanghai, C&EN Volume 84 Issue 34 | pp. 15-22 Issue Date: August 21, 2006
Ideales Umfeld – Für Rittal und Bicoll bleibt Shanghai der Drachenkopf, China Contact 9/2006, pp. 12-13
Biotechnologie made in China, GoingPublic, special edition “Biotechnologie 2005”, pp. 62-64
Heilung aus der Hexenküche, Berliner Tagesspiegel, 22.11.2006, page 28, http://www.tagesspiegel.de/weltspiegel/gesundheit/heilung-aus-der-hexenkueche/777744.html
China Strides Toward Global Pharma Role, Chemical & Engineering News, Volume 85, Number 11, pp. 15-19
Shanghai Revisted, Chemical & Engineering News, Volume 85, Number 19, p. 5
Chinese plants for modern drug discovery campaigns, Chimica Oggi/CHEMISTRY TODAY, Volume 25, Number 5, Insert: Outsourcing from China Authors: Dr. Christian Haug, Dr. Nicole Feling, Dr. Kai Lamottke
Medikamentenentwicklung – Naturstoffe aus China, transkript, 14. Jahrgang, 6/2008, pp. 40-41 Authors: Dr. Kai Lamottke, Dr. Christian Haug, Dr. Nicole Feling
The right match – German SMEs: Challenges, Strategies and Success in a Competitive China, GC Ticker: bi-monthly newsletter of the German Chamber of Commerce, 4, 2010, p. 35
Publications by Bicoll
The roots of innovation – Can we afford to turn away from natural product drug discovery research?, European Biopharmaceutical Review, January 2011, p.52
Working in the Chinese Drug Industry, Chemical & Engineering News, 89(7), February 14, 2011
The Identification of Naturally Occurring Neoruscogenin as a Bioavailable, Potent and High-Affinity Agonist of the Nuclear Receptor RORa (NR1F1), S. Helleboid, C. Haug, K. Lamottke, Y. Zhou, J. Wei, S. Daix, L. Cambula, G. Rigou, D. W. Hum, R. Walczak, Journal of Biomolecular Screening, Jul 2013, DOI: 10.1177/1087057113497095.
Evaluation of the Anti-inflammatory and Anti-oxidative Potential of Four Fern Species from China Intended for Use as Food Supplements, C. Dion, C. Haug, H. Guan, C. Ripoll, P. Spiteller, A. Coussaert, E. Boulet, D. Schmidt, J. Wei, Y. Zhou, K. Lamottke, Natural product communications, 10(4), 597-603, April 2015. https://doi.org/10.1177/1934578X1501000416
Slow horses and hidden champions in the drug discovery field K. Lamottke, April 2015 DOI:10.13140/RG.2.1.4137.4242
MicroRNAs in epilepsy: pathophysiology and clinical utility, Prof. David C. Henshall, Prof. Hajo M. Hamer, MD, Prof. R. Jeroen Pasterkamp, PhD, Prof. David B. Goldstein, PhD, Prof. Jørgen Kjems, PhD, Prof. Jochen H. M. Prehn, PhD, Stephanie Schorge, PhD, Kai Lamottke, PhD, Felix Rosenow, MD, THE LANCET Neurology, Dec. 2016, DOI: http://dx.doi.org/10.1016/S1474-4422(16)30246.
Public impulses to support biotechnology: Healthcare system in China, “Öffentlich getriebene Impulse zur Unterstützung der Biotechnologie”, M. Lamottke, Y. Zhou, “Das Gesundheitswesen in China” Medizinisch Wissentschaftliche Verlagsgesellschaft, 2017, Pp. 165-179 ISBN: 978-3-95466-303-3
BICS01 Mediates Reversible Anti-seizure Effects in Brain Slice Models of Epilepsy, G. Morris, M. Heiland, K. Lamottke, H. Guan, T. D. M. Hill, Y. Zhou, Q. Zhu, S. Schorge, D. C. Henshall, Frontiers in Neurology, Jan. 2022, DOI: https://doi.org/10.3389/fneur.2021.791608 or download here
Fractionation and Extraction Optimization of Potentially Valuable Compounds and Their Profiling in Six Varieties of Two Nicotiana Species, by Csaba Laszlo, Kacper Kaminski, Haifeng Guan, Maria Fatarova, Jianbing Wei, Alexandre Bergounioux, Walter K. Schlage, Sandra Schorderet-Weber, Philippe A. Guy, Nikolai V. Ivanov, Kai Lamottke and Julia Hoeng, Molecules 2022, 27(22), 8105, Nov. 2022, DOI: https://doi.org/10.3390/molecules27228105 or download here